Article
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
29 Oct 2014
Abstract excerpt
Genetic engineering of T cells for adoptive transfer by introducing a tumor-targeting chimeric antigen receptor (CAR) is a new approach to cancer immunotherapy. A challenge for the field is to define cell surface molecules that are both preferentially expressed on tumor cells and can be safely targeted with T cells. The orphan tyrosine kinase receptor ROR1 is a candidate target for T-cell therapy with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
